Compare ITT & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITT | ASND |
|---|---|---|
| Founded | 1920 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 12.2B |
| IPO Year | N/A | 2015 |
| Metric | ITT | ASND |
|---|---|---|
| Price | $176.62 | $209.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $203.89 | ★ $256.40 |
| AVG Volume (30 Days) | ★ 1.2M | 794.8K |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | ★ 2.16 | N/A |
| EPS | ★ 5.99 | N/A |
| Revenue | ★ $3,813,500,000.00 | $758,592,045.00 |
| Revenue This Year | $7.91 | $99.74 |
| Revenue Next Year | $5.90 | $79.40 |
| P/E Ratio | $29.46 | ★ N/A |
| Revenue Growth | 8.01 | ★ 97.46 |
| 52 Week Low | $105.64 | $118.03 |
| 52 Week High | $197.07 | $229.94 |
| Indicator | ITT | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 52.35 |
| Support Level | $171.64 | $197.16 |
| Resistance Level | $176.52 | $213.22 |
| Average True Range (ATR) | 4.87 | 10.30 |
| MACD | 0.09 | -0.44 |
| Stochastic Oscillator | 60.07 | 45.54 |
ITT began its journey as International Telephone & Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT Inc. sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposures to North America, Europe, and Asia.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.